Toward “Serolomics”: Papillomavirus Serology Is Taking a Technologic Lead in High-Throughput Multiplexed Antibody Analysis

Dillner, Joakim

doi:10.1373/clinchem.2005.055483

Cited by 8 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurement of HPV serological and neutralizing antibodies in individuals with FA is one of the best approaches to measure the protective effect of HPV vaccines as well as monitoring response to natural infection [38]. The antibody response to HPV is generally type-specific.…”

Section: Discussionmentioning

confidence: 99%

Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia

Mehta

Sauter

Zhang

et al. 2017

Vaccine

View full text Add to dashboard Cite

Fanconi anemia (FA) is a rare genetic disorder associated with predisposition to head and neck and gynecological squamous cell cancers. In the general population, these cancers are commonly linked to human papillomavirus (HPV) infection. Antibodies to natural HPV infection and HPV vaccination were evaluated in 63 individuals with FA while considering host immune factors. Approximately 30% of reportedly unvaccinated participants were seropositive (HPV6–38%, HPV11–25%, HPV16–26%, and HPV18–26%). Seropositivity was significantly associated with having had sex regardless of age (p=0.007). Most participants showed seropositivity after HPV vaccination (HPV6–100%, HPV11–100%, HPV16–100% and HPV18–92%). Interestingly, titers for all 4 subtypes were significantly lower in the post-hematopoietic stem cell transplant (HSCT) participants compared to those who received the vaccine, but had not undergone HSCT (HPV6- p=0.030, HPV11-p=0.003, HPV16-p=0.018, HPV18-p=<0.001). It is unclear if these titers sufficiently protect from new infection since protective serologic cut offs have not yet been defined for the HPV vaccine. Individual immune functions were not associated with HPV seropositivity, however, underlying heterogeneous immune deficiency may explain higher rates of seropositivity in our younger unvaccinated participants (age 4–13 years). To better measure the efficacy of HPV vaccination in those with FA and other immune-compromised or cancer-prone disorders, future well-controlled vaccine studies are required.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia

Mehta

Sauter

Zhang

et al. 2017

Vaccine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Multiplex serology allows quantitative analysis of antibodies to multiple recombinant structural and regulatory proteins in parallel in a high-throughput fashion (Dillner, 2005; Waterboer et al , 2005). This increases the sensitivity and in comparison with conventional screening ELISA increases the specificity of antibody detection as it has been shown for HPV (Dillner, 2005; Waterboer et al , 2005), polyomaviruses (Kjaerheim et al , 2007) and Helicobacter pylori (Michel et al , 2009). The protein antigens used in the assay for our analysis have been shown to allow very sensitive and virus-type-specific antibody detection (Waterboer et al , 2005; Kjaerheim et al , 2007; Paulson et al , 2010; Liang et al , 2012; Teras et al , 2015).…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers of polyomavirus infection and risk of lung cancer in never smokers

et al. 2016

View full text Add to dashboard Cite

Background:Lung cancer in never smokers is a significant contributor of cancer mortality worldwide. In this analysis, we explored the role of nine human polyomaviruses, including JC virus (JCV), BK virus (BKV) and Merkel cell virus (MCV), in lung cancer development in never smokers as there are data to support that polyomaviruses are potentially carcinogenic in the human lung.Methods:We used multiplex serology to detect serum antibodies to polyomaviruses in a nested case–control design combining lung cancer cases and controls from four cohort studies – NYU Women's Health Study (NYU-WHS), Janus Serum Bank, Shanghai Women's Health Study and Singapore Chinese Health Study (SCHS).Results:The final analyses included 511 cases and 508 controls. Seroprevalence for each polyomavirus showed significant heterogeneity by study, but overall there were no statistically significant differences between cases and controls. In total, 69.1% of the cases and 68.7% of the controls were seropositive for JCV VP1 antibody. Seropositivity for BKV was higher at 89.0% in cases and 89.8% in controls and lower for MCV at 59.3% in cases and 61.6% in controls. Similar results were obtained after adding an additional retrospective case–control study (Xuanwei study) to the analysis.Conclusions:Our results do not support the hypothesis that seropositivity for polyomaviruses is associated with increased lung cancer risk in never smokers. Future research to evaluate relationship between polyomavirus infection and lung carcinogenesis should focus more on evaluating the presence of virus or viral nucleic acids (DNA or RNA) in lung tumour samples.

show abstract

“…Therefore, these ILs could potentially be used as markers of infection and, in combination with viral markers, could aid in the early diagnosis of HCV infection. Finally, the possibility of a new field of research -'serolomics' -has been raised [50]. It anticipates the expansion of diagnostics based on multiplexed analysis of markers of infection present in serum.…”

Section: Other Approachesmentioning

confidence: 99%

Antibody- and genome-based identification of recent HCV infection

Araujo

2012

Antivir Ther

View full text Add to dashboard Cite

The diagnosis of recent HCV infection remains challenging due to the absence of serological markers specific to the early phase of infection. Clinical follow-up and seroconversion to anti-HCV immunoglobulin (Ig)G, detection of viral RNA and changes in levels of blood biomarkers associated with liver pathology provide circumstantial evidence of recent HCV infection. Studies based on anti-HCV IgG avidity, antigen-specific antibody profiling, HCV viral load fluctuations and signature changes in the HCV genome show potential to discriminate recent from persistent HCV infection. These markers require further evaluation and would necessitate use of samples from infected people originating from broad clinical and epidemiological contexts.

show abstract

Toward “Serolomics”: Papillomavirus Serology Is Taking a Technologic Lead in High-Throughput Multiplexed Antibody Analysis

Cited by 8 publications

References 9 publications

Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia

Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia

Serum biomarkers of polyomavirus infection and risk of lung cancer in never smokers

Antibody- and genome-based identification of recent HCV infection

Contact Info

Product

Resources

About